Several possible studies
Story checked
The Most Promising New Drug for Lowering a Dangerous Type of Cholesterol Didn’t Work. Now What? (opens in a new tab)
menshealth.com · 2026-09-10
Short answer
Several possible studiesNo clear answer.
More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.
Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.
Share this check
The story
The Most Promising New Drug for Lowering a Dangerous Type of Cholesterol Didn’t Work. Now What?
menshealth.com · 2026-09-10
The story’s checkable claims.
Read the original story (opens in a new tab)NewsLink checks it
Several studies could be the source of this story.
More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.
Open claim evidenceSearch result
Several studies could fit.
More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.
Evidence layer
Claim by claim
What the story asserts. With no source study, there is nothing to check these against.
Reading mode
Scan verdicts. Open evidence only when needed.
Claim 1 of 5Not checkedOn September 4, Novartis announced that pelacarsen, a drug targeting lipoprotein(a), failed to significantly reduce the risk of cardiovascular death, heart attack, or stroke.View evidenceHide evidence
As statedfailed to significantly reduce risk
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 2 of 5Not checkedThe trial of pelacarsen, called Lp(a)HORIZON, enrolled more than 8,300 patients with established cardiovascular disease and elevated lipoprotein(a), randomized them to pelacarsen or placebo on top of standard care, and followed them over several years.View evidenceHide evidence
As statedmore than 8,300 patients
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 3 of 5Not checkedThe negative result raises the possibility that lipoprotein(a) may be a marker of cardiovascular risk rather than a cause.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 4 of 5Not checkedThe article says full data are expected later this year, and it is possible the trial could still show benefit in some subgroup or with longer follow-up or earlier intervention.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 5 of 5Not checkedThe story notes that other Lp(a)-lowering drugs, including olpasiran and lepodisiran, are still in clinical trials and may have different results.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Method layer
No single source study was found.
NewsLink still surfaces nearby research so you can inspect the field instead of a single paper.
Nearby research
No exact source, but these papers are close.
PubMed, Europe PMC, Crossref · 15 candidate papers
Enhancing representation in cardiovascular trials: Lessons from Lp(a)FRONTIERS EXPANSION in United States Black and Hispanic patients with elevated lipoprotein(a) and established atherosclerotic cardiovascular disease.
American Journal of Preventive Cardiology · 2026 · PubMed
Lipoprotein(a) Lowering with Pelacarsen (TQJ230)
Cardiovascular & Hematological Disorders Drug Targets · 2025 · PubMed, Europe PMC, Crossref
Lipoprotein(a) in Coronary Artery Disease and Aortic Stenosis: Pathophysiology, Clinical Impact, Interventional Implications and Emerging Targeted Therapies.
2026 · Europe PMC
From physiopathology to treatment of familial hypercholesterolemia: Existing and emerging pharmacotherapies.
Pharmacological Reviews · 2026 · PubMed
Pelacarsen. Antisense oligonucleotide targeting apolipoprotein(a), Treatment of lipoprotein disorders, Treatment of cardiovascular diseases
Drugs of the Future · 2022 · Crossref
And 10 more candidates considered.